2/19/2014 | SP | New Issue: Citigroup prices $11.32 million 12.18% airbag autocallables linked to Momenta
|
2/12/2014 | SP | Citigroup to price 9.5%-12% airbag autocallables linked to Momenta
|
12/12/2008 | PP | New Issue: Momenta plans $25.2 million direct placement of stock
|
12/12/2008 | PP | Market Commentary: Enterprise raises $25 million, sees $62 million more; Empyrean gets $10 million line; Momenta sells stock
|
1/26/2007 | CVHY | Momenta files $150 million debt securities, stock shelf
|
11/3/2006 | BT | Momenta ends quarter with $202 million cash; net loss doubles to $12.0 million
|
9/14/2006 | BT | Momenta to begin clinical trial of anticoagulant this fall
|
8/22/2006 | BT | Momenta names Craig Wheeler as its new chief executive officer
|
8/11/2006 | BT | Momenta says FDA review of M-Enoxaparin still in progress, awaits outcome of patent litigation case
|
8/8/2006 | BT | Sandoz', Momenta's generic Lovenox challenged by Aventis
|
7/31/2006 | BT | Momenta files Investigational New Drug application for anticoagulant to treat acute coronary syndrome
|
7/25/2006 | BT | Momenta, Sandoz collaborate to develop follow-on and generic drugs
|
7/25/2006 | BT | Market Commentary: Encysive plunges 40%; Momenta gains 38%; Nastech rises; Enzon up; Connetics firms
|
7/25/2006 | PP | Market Commentary: Brookdale Senior Living pockets $650 million; Momenta secures $74.87 million from collaboration deal
|
7/25/2006 | BTPP | New Issue: Momenta makes $74.87 million stock sale as part of collaboration
|
7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
5/26/2006 | BT | Market Commentary: Anadys spikes on thin volume; Cubist extends gain on Cubicin nod; Tanox, Momenta, Epix up
|
11/8/2005 | BT | Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
|
8/30/2005 | BT | Market Commentary: Amylin loses 3% after follow-on; Manhattan Pharma taps PIPEs; Momenta sold on news; ViaCell off
|
7/29/2005 | BT | Market Commentary: Advanced Life Sciences, Avalon IPOs delayed; ZymoGenetics on deck for Wed; stem cell names rise
|
7/22/2005 | BT | Market Commentary: Momenta gains at open, then goes south; Adams up against market; Durect convertibles up on buyback
|
7/21/2005 | BT | Market Commentary: Adams IPO zooms; Accentia stalls, again; Guilford up on MGI Pharma merger; Momenta on tap; Isis rises
|
7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
7/18/2005 | BT | Momenta Pharmaceuticals announces 4 million-share follow-on offering
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
7/1/2005 | BT | Momenta Pharmaceuticals files $125 million stock shelf
|